The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1283
Nilotinib (Tasigna) for CML
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

Nilotinib (Tasigna – Novartis), a tyrosine kinase inhibitor, has been approved by the FDA for treatment of Philadelphia chromosome-positive (Ph+) chronic or accelerated phase chronic myelogenous leukemia (CML) in patients resistant to or intolerant of imatinib (Gleevec).

STANDARD TREATMENT — Imatinib, the first tyrosine kinase inhibitor for treatment of CML, was approved by the FDA in 2001.1 It is now the standard first-line treatment for all phases of Ph+ CML. Primary treatment of chronic phase CML with imatinib results in a complete cytogenetic response rate of 87% and an overall survival rate of 89% at 5 years.2 Patients who do not respond to imatinib may be treated with higher doses of imatinib, another tyrosine kinase inhibitor, or allogeneic stem-cell transplantation. Dasatinib (Sprycel), the second tyrosine kinase inhibitor for treatment of CML, ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Nilotinib (Tasigna) for CML
Article code: 1283b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian